The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial. [electronic resource]
Producer: 20100329Description: 1709-11 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Lymphoma, Mantle-Cell -- drug therapy
- Male
- Middle Aged
- Prognosis
- Rituximab
- Severity of Illness Index
- Survival
- Treatment Outcome
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Letter; Randomized Controlled Trial; Validation Study
There are no comments on this title.
Log in to your account to post a comment.